These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33088647)

  • 1. Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes.
    Komatsu H; Enomoto M; Shiraishi H; Morita Y; Hashimoto D; Nakayama S; Funakoshi S; Hirano S; Terada Y; Miyamura M; Fujimoto S
    Diabetol Int; 2020 Oct; 11(4):388-392. PubMed ID: 33088647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoglycemia during the Concomitant Use of Repaglinide and Clopidogrel in an Elderly Patient with Type 2 Diabetes and Severe Renal Insufficiency.
    Takayama K; Fujii K; Yamaguchi H; Miyoshi Y; Uehara Y; Nagata S; Obata Y; Kosugi M; Hazama Y; Yasuda T
    Intern Med; 2021; 60(6):905-910. PubMed ID: 33716254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction to: Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes.
    Komatsu H; Enomoto M; Shiraishi H; Morita Y; Hashimoto D; Nakayama S; Funakoshi S; Hirano S; Terada Y; Miyamura M; Fujimoto S
    Diabetol Int; 2020 Oct; 11(4):393. PubMed ID: 33090124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe hypoglycemia from clarithromycin-repaglinide drug interaction.
    Khamaisi M; Leitersdorf E
    Pharmacotherapy; 2008 May; 28(5):682-4. PubMed ID: 18447665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
    Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
    Johansen OE; Birkeland KI
    Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination.
    Elling R; Spehl MS; Wohlfarth A; Auwaerter V; Hermanns-Clausen M
    Clin Toxicol (Phila); 2016; 54(2):158-60. PubMed ID: 26692235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.
    Roustit M; Blondel E; Villier C; Fonrose X; Mallaret MP
    Ann Pharmacother; 2010 Apr; 44(4):764-7. PubMed ID: 20197475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
    Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
    Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious hypoglycemia associated with misuse of repaglinide.
    Flood TM
    Endocr Pract; 1999; 5(3):137-8. PubMed ID: 15251685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
    Hatorp V; Hansen KT; Thomsen MS
    J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
    Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
    Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R
    MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.